Novo Nordisk: Court Victory and Pill Approval Propel Recovery, Yet 2026 Revenue Slump Casts a Shadow
Novo Nordisk has been handed a series of catalysts in quick succession — a landmark patent ruling in…
Denmark’s Growth Upgrade and a DKK 11.2bn Buyback Propel Novo Nordisk’s Narrative
Copenhagen revises 2026 GDP forecast to 2.7% on booming pharma led by Novo Nordisk, despite US pricing headwinds…